NR3C2 and Hypokalemia: If patients develop hypokalemia on osilodrostat therapy, the consensus was to consider adding spironolactone or eplerenone to block cortisol and adrenal steroid precursor activation of mineralocorticoid receptors and/or add potassium supplements (Table 1 and Fig. 4, statement 24).